ATE184792T1 - 2-bromomelatonin zur behandlung von schlafstörungen - Google Patents

2-bromomelatonin zur behandlung von schlafstörungen

Info

Publication number
ATE184792T1
ATE184792T1 AT95118386T AT95118386T ATE184792T1 AT E184792 T1 ATE184792 T1 AT E184792T1 AT 95118386 T AT95118386 T AT 95118386T AT 95118386 T AT95118386 T AT 95118386T AT E184792 T1 ATE184792 T1 AT E184792T1
Authority
AT
Austria
Prior art keywords
bromomelatonin
sleep disorders
treatment
therapy
pharmaceutical compositions
Prior art date
Application number
AT95118386T
Other languages
English (en)
Inventor
Gabriele Biella
Franco Fraschini
Bojidar Stanvok
Strambi Luigi Ferini
Original Assignee
Franco Fraschini
Stankov Bojidar
I F L O Istituto Farmacologico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Franco Fraschini, Stankov Bojidar, I F L O Istituto Farmacologico filed Critical Franco Fraschini
Application granted granted Critical
Publication of ATE184792T1 publication Critical patent/ATE184792T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT95118386T 1991-05-13 1992-05-11 2-bromomelatonin zur behandlung von schlafstörungen ATE184792T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Publications (1)

Publication Number Publication Date
ATE184792T1 true ATE184792T1 (de) 1999-10-15

Family

ID=11359886

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92107865T ATE142877T1 (de) 1991-05-13 1992-05-11 Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
AT95118386T ATE184792T1 (de) 1991-05-13 1992-05-11 2-bromomelatonin zur behandlung von schlafstörungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92107865T ATE142877T1 (de) 1991-05-13 1992-05-11 Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie

Country Status (9)

Country Link
US (1) US5430029A (de)
EP (2) EP0713701B1 (de)
JP (1) JPH05155769A (de)
AT (2) ATE142877T1 (de)
DE (2) DE69213814T2 (de)
DK (2) DK0713701T3 (de)
ES (2) ES2139132T3 (de)
GR (2) GR3022060T3 (de)
IT (1) IT1251544B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190490T1 (de) * 1990-09-28 2000-04-15 I F L O S A S Di Giorgio E Ald Kontrazeptives und menstruationszyklus regulierendes präparat mit onkostatischen eigenschaften
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IT1262912B (it) * 1992-12-30 1996-07-22 Impiego della melatonina nella terapia della sclerosi sistemica, della sarcoidosi ed altro
AU726758B2 (en) * 1993-11-18 2000-11-23 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5763471A (en) * 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
WO1996023496A1 (en) * 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
FR2787447B1 (fr) * 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AP2001002245A0 (en) * 1999-02-05 2001-09-30 Univ Manchester Regulation of anesthesia.
US6638966B2 (en) 2000-09-19 2003-10-28 University Of Iowa Research Foundation Use of melatonin analogues for induction of general anesthesia
US6552064B2 (en) * 2000-09-19 2003-04-22 University Of Iowa Research Foundation Use of melatonin for induction of general anesthesia
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
WO2005060968A1 (en) * 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
WO2005084664A1 (ja) * 2004-03-08 2005-09-15 Kanazawa University Technology Licensing Organization Ltd. インドール誘導体及びその用途
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3085116C (en) 2012-01-26 2022-07-19 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
JP2025526852A (ja) * 2022-02-16 2025-08-15 ラ ファーマテック インコーポレイテッド 不眠症の治療のための新規医薬組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
FI900801A7 (fi) * 1987-08-17 1990-02-16 Nelson Res & Development Co Melantoniinianalogit

Also Published As

Publication number Publication date
DE69230046T2 (de) 2000-05-31
DE69213814D1 (de) 1996-10-24
ATE142877T1 (de) 1996-10-15
ES2139132T3 (es) 2000-02-01
IT1251544B (it) 1995-05-17
DE69230046D1 (de) 1999-10-28
DK0713701T3 (da) 2000-04-03
US5430029A (en) 1995-07-04
EP0713701B1 (de) 1999-09-22
ITMI911299A0 (it) 1991-05-13
EP0513702A2 (de) 1992-11-19
ITMI911299A1 (it) 1992-11-13
DK0513702T3 (da) 1996-12-30
EP0513702B1 (de) 1996-09-18
EP0713701A1 (de) 1996-05-29
JPH05155769A (ja) 1993-06-22
GR3022060T3 (en) 1997-03-31
ES2093735T3 (es) 1997-01-01
GR3032207T3 (en) 2000-04-27
DE69213814T2 (de) 1997-04-03
EP0513702A3 (de) 1992-11-25

Similar Documents

Publication Publication Date Title
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE69738948D1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
DE69117117D1 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
DE69120933D1 (de) Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.